Ligand Pharmaceuticals Incorporated
LGNDNASDAQHealthcare● Active
$238.65
+$1.65(+0.70%)
Market Cap$4.8B
P/E Ratio—
52W High$247.38
52W Low$102.5
Ligand Pharmaceuticals Incorporated (LGND) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LGND · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$1.63
Est. $1.84 · -11.4%
Revenue
$0.05B
Est. $0.06B · -12.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
LGND reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.40
Rev. $5.46B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.40
Rev. Est.$5.46B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $1.97 | — | — | — | $0.06B | — |
| ▼ Q2 FY2026 | May 14, 2026 | $1.84 | $1.63 | -11.4% | $0.05B | $0.06B | -12.5% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $1.46 | $2.02 | +38.4% | $0.06B | $0.06B | +7.3% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $1.97 | $3.09 | +56.9% | $0.12B | $0.06B | +107.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $1.54 | $1.60 | +3.9% | $0.05B | $0.05B | -9.8% |
| ▲ Q2 FY2025 | May 8, 2025 | $1.30 | $1.33 | +2.3% | $0.05B | $0.04B | +2.3% |
| ▼ Q1 FY2025 | Feb 27, 2025 | $1.37 | -$1.64 | -219.7% | $0.04B | $0.04B | +21.3% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.75 | -$0.39 | -152.0% | $0.05B | $0.04B | +32.8% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$1.97
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
$1.63
EPS Est.
$1.84
EPS Surpr.
-11.4%
Revenue
$0.05B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$2.02
EPS Est.
$1.46
EPS Surpr.
+38.4%
Revenue
$0.06B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$3.09
EPS Est.
$1.97
EPS Surpr.
+56.9%
Revenue
$0.12B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$1.60
EPS Est.
$1.54
EPS Surpr.
+3.9%
Revenue
$0.05B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$1.33
EPS Est.
$1.30
EPS Surpr.
+2.3%
Revenue
$0.05B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$1.64
EPS Est.
$1.37
EPS Surpr.
-219.7%
Revenue
$0.04B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.39
EPS Est.
$0.75
EPS Surpr.
-152.0%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.86 | $3.18 | $3.45 | 1 |
| Q3 FY2027 | $2.65 | $2.95 | $3.20 | 1 |
| Q2 FY2027 | $2.38 | $2.65 | $2.87 | 1 |
| Q1 FY2027 | $2.07 | $2.30 | $2.49 | 1 |
| Q4 FY2026 | $2.58 | $2.87 | $3.12 | 1 |
| Q3 FY2026 | $2.39 | $2.50 | $2.62 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -11.4% | $221.21 | $218.98 | -1.01% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +38.4% | $191.39 | $196.17 | +2.50% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +56.9% | $190.38 | $208.22 | +9.37% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +3.9% | $142.40 | $146.32 | +2.75% |
| ▲ Q2 FY2025 | May 8, 2025 | +2.3% | $105.62 | $102.51 | -2.94% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -219.7% | $115.01 | $115.67 | +0.57% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -152.0% | $116.90 | $129.90 | +11.12% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +27.3% | $98.13 | $99.04 | +0.93% |
Q2 FY2026-1.01%
Report Date
May 14, 2026
EPS Beat/Miss
-11.4%
Price Before
$221.21
Price After
$218.98
Q1 FY2026+2.50%
Report Date
Feb 26, 2026
EPS Beat/Miss
+38.4%
Price Before
$191.39
Price After
$196.17
Q4 FY2025+9.37%
Report Date
Nov 6, 2025
EPS Beat/Miss
+56.9%
Price Before
$190.38
Price After
$208.22
Q3 FY2025+2.75%
Report Date
Aug 7, 2025
EPS Beat/Miss
+3.9%
Price Before
$142.40
Price After
$146.32
Q2 FY2025-2.94%
Report Date
May 8, 2025
EPS Beat/Miss
+2.3%
Price Before
$105.62
Price After
$102.51
Q1 FY2025+0.57%
Report Date
Feb 27, 2025
EPS Beat/Miss
-219.7%
Price Before
$115.01
Price After
$115.67
Q4 FY2024+11.12%
Report Date
Nov 7, 2024
EPS Beat/Miss
-152.0%
Price Before
$116.90
Price After
$129.90
Q3 FY2024+0.93%
Report Date
Aug 6, 2024
EPS Beat/Miss
+27.3%
Price Before
$98.13
Price After
$99.04
Avg Beat Reaction+2.52%
Avg Miss Reaction+3.56%
Beat Rate5 / 8 quarters
Largest Move+11.12% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LGND ends December
Ligand Pharmaceuticals Incorporated (LGND) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $1.63 — missing the analyst consensus of $1.84 by -11.4%. The next LGND earnings date is expected around September 1, 2026.
Each quarter, investors track LGND earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LGND revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LGND's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LGND earnings · 5 questionsLigand Pharmaceuticals Incorporated's next earnings report is expected around September 1, 2026. LGND typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LGND historically reports after market close (AMC).
LGND earnings datewhen is LGND earningsLGND next earnings datewhen does LGND report earningsLGND earnings calendar
▸ Source: FMP · Ligand Pharmaceuticals Incorporated SEC filings · US GAAP · Ligand Pharmaceuticals Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026